XYREM Drug Patent Profile

Which patents cover Xyrem, and what generic alternatives are available?

Xyrem is a drug marketed by Jazz Pharms and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-four patent family members in twenty-one countries.

The generic ingredient in XYREM is sodium oxybate. There are one thousand four hundred and seventy-two drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the sodium oxybate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Xyrem

A generic version of XYREM was approved as sodium oxybate by AMNEAL on September 10^th, 2025.

Summary for XYREM

International Patents:	34
US Patents:	7
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for XYREM

Paragraph IV (Patent) Challenges for XYREM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XYREM	Oral Solution	sodium oxybate	500 mg/mL	021196	1	2010-07-08

US Patents and Regulatory Information for XYREM

XYREM is protected by seven US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Jazz Pharms	XYREM	sodium oxybate	SOLUTION;ORAL	021196-001	Jul 17, 2002	AA	RX	Yes	Yes
Jazz Pharms	XYREM	sodium oxybate	SOLUTION;ORAL	021196-001	Jul 17, 2002	AA	RX	Yes	Yes					Y
Jazz Pharms	XYREM	sodium oxybate	SOLUTION;ORAL	021196-001	Jul 17, 2002	AA	RX	Yes	Yes					Y
Jazz Pharms	XYREM	sodium oxybate	SOLUTION;ORAL	021196-001	Jul 17, 2002	AA	RX	Yes	Yes
Jazz Pharms	XYREM	sodium oxybate	SOLUTION;ORAL	021196-001	Jul 17, 2002	AA	RX	Yes	Yes					Y
Jazz Pharms	XYREM	sodium oxybate	SOLUTION;ORAL	021196-001	Jul 17, 2002	AA	RX	Yes	Yes					Y
Jazz Pharms	XYREM	sodium oxybate	SOLUTION;ORAL	021196-001	Jul 17, 2002	AA	RX	Yes	Yes					Y

International Patents for XYREM

See the table below for patents covering XYREM around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2014223373	Administration of gamma hydroxybutyrate with monocarboxylate transporters
Brazil	112015021012	administração de gama hidroxibutirato com transportador de monocarboxilatos
Canada	2902948	ADMINISTRATION D'ACIDE 4-HYDROXYBUTANOIQUE ET DE TRANSPORTEURS MONOCARBOXYLATE (ADMINISTRATION OF GAMMA HYDROXYBUTYRATE WITH MONOCARBOXYLATE TRANSPORTERS)
China	105073106	Administration of gamma hydroxybutyrate with monocarboxylate transporters
China	111317730	γ羟基丁酸与单羧酸转运蛋白的施用 (Administration of gamma hydroxybutyrate with monocarboxylate transporters)
Cyprus	1120086
Cyprus	1122992

Supplementary Protection Certificates for XYREM

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1948158	1690020-1	Sweden		PRODUCT NAME: SACUBITRIL AND VALSARTAN, AS SACUBITRIL VALSARTAN SODIUM SALT COMPLEX, I.E. TRISODIUM 3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3- ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3-METHYL-2- (PENTANOYL2-(TETRAZOL-5-YLATE)BIPHENYL-4- YLMETHYLAMINO)BUTYRATE HEMIPENTAHYDRATE; REG. NO/DATE: EU/1/15/1058 20151123
1713823	92595	Luxembourg		PRODUCT NAME: SIMEPREVIR, OU L UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, INCLUANT SIMEPREVIR SODIUM. FIRST REGISTRATION: 20140516
2673237	SPC/GB19/027	United Kingdom		PRODUCT NAME: SODIUM ZIRCONIUM CYCLOSILICATE; REGISTERED: UK EU/1/17/1173(NI) 20180326; UK PLGB17901/0331-0001 20180326; UK PLGB17902/0332-0001 20180326
0579826	SPC/GB02/042	United Kingdom		PRODUCT NAME: ERTAPENEM ((1R,5S,6S,8R,2'S,4'S)-2-(2-(3-CARBOXYPHENYLCARBAMOYL)PYRROLIDIN-4-YLTHIO)-6-(1-HYDROXYETHYL)-1-METHYLCARBAPENEM-3-CARBOXYLIC ACID), A PHARMACEUTICALLY ACCEPTABLE SALT OR IN VIVO HYDROLYSABLE ESTER THEREOF, ESPECIALLY AS THE MONOSODIUM SALT ERTA; REGISTERED: UK EU/1/02/216/001 20020422
2822954	18C1035	France		PRODUCT NAME: BICTEGRAVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER BICTEGRAVIR DE SODIUM; REGISTRATION NO/DATE: EU/1/18/1289 20180625
0290047	SPC/GB97/078	United Kingdom		PRODUCT NAME: MANGAFODIPIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR MANGAFODIPIR TRISODIUM; REGISTERED: UK EU/1/97/040/001 19970522; UK EU/1/97/040/002 19970522
1856135	2020/017	Ireland		PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REGISTRATION NO/DATE: EU/1/19/1405 20200113

Xyrem: Market Landscape and Patent Exclusivity Analysis

Last updated: February 19, 2026

Xyrem (sodium oxybate) is a central nervous system depressant prescribed for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy. This analysis details Xyrem's market position, patent portfolio, and competitive landscape to inform R&D and investment strategies.

What is Xyrem's Current Market Position?

Xyrem is the leading therapeutic option for narcolepsy in the United States. Its efficacy in managing the core symptoms of the disorder, particularly cataplexy, has established a strong prescriber base and patient loyalty.

Key Market Metrics

• Indication: Narcolepsy with cataplexy and excessive daytime sleepiness.
• Manufacturer: Jazz Pharmaceuticals.
• Market Share: Dominant in the narcolepsy treatment market, with limited direct competition for its specific indications.
• Sales: Xyrem generated approximately $1.3 billion in net sales in 2022. [1] This represents a significant portion of Jazz Pharmaceuticals' overall revenue.
• Patient Population: The prevalence of narcolepsy is estimated to be between 40,000 to 70,000 individuals in the U.S., with a significant percentage diagnosed and treated. [2]

Therapeutic Advantages

Xyrem's mechanism of action involves increasing the amount of slow-wave sleep, thereby improving sleep quality and reducing the frequency of cataplexy. Unlike stimulant medications that address excessive daytime sleepiness, Xyrem targets the underlying sleep dysregulation associated with narcolepsy.

What is Xyrem's Patent and Exclusivity Landscape?

Xyrem's market exclusivity is supported by a robust patent portfolio and regulatory exclusivities. Understanding these protections is crucial for assessing the timeline of generic entry and potential revenue erosion.

Key Patents and Exclusivities

• US Patent 6,716,867: This is a foundational patent covering the use of sodium oxybate for treating cataplexy and/or excessive daytime sleepiness in patients with narcolepsy. It was issued on April 6, 2004.
• US Patent 7,718,700: This patent relates to a method of reducing or eliminating the impact of cataplexy and/or excessive daytime sleepiness. It was issued on May 18, 2010.
• US Patent 8,541,444: This patent covers a pharmaceutical composition comprising sodium oxybate. It was issued on September 24, 2013.
• Orange Book Exclusivities: Xyrem has benefited from various forms of regulatory exclusivity, including New Chemical Entity (NCE) exclusivity and Orphan Drug Exclusivity (ODE). [3] ODE provides seven years of market exclusivity for drugs treating rare diseases, and Xyrem qualified for this due to narcolepsy being considered a rare condition.

Patent Litigation and Generic Entry

Jazz Pharmaceuticals has actively defended its patents through litigation against potential generic entrants. The legal battles have focused on various patent claims and have resulted in a complex timeline for generic market entry.

• ANDA Litigation: Abbreviated New Drug Application (ANDA) proceedings have been filed by multiple generic manufacturers.
• District Court Rulings: Various district court decisions have found some of Jazz's patents to be invalid or not infringed.
• Federal Circuit Appeals: Appeals to the U.S. Court of Appeals for the Federal Circuit have led to mixed outcomes, often remanding cases for further review.
• Authorized Generic: Jazz Pharmaceuticals has also utilized authorized generics to manage the transition to generic competition. An authorized generic is a generic version of a branded drug that is marketed by the brand-name company or its affiliate.

The current landscape indicates that generic versions of Xyrem have begun to enter the market, primarily through settlement agreements and the expiration of certain patent protections. However, the full impact of generic competition is still unfolding.

What is the Competitive Landscape for Narcolepsy Treatments?

While Xyrem has held a dominant position, the competitive landscape is evolving with the introduction of new therapeutic modalities and the eventual availability of generics.

Direct Competitors (Marketed Products)

• Wakix (pitolisant): Marketed by Harmony Biosciences, Wakix is a first-in-class histamine H3 receptor antagonist/inverse agonist approved for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy. It received FDA approval in 2019. [4] Wakix offers a non-scheduled alternative to Xyrem and is approved for both cataplexy and excessive daytime sleepiness.
• Modafinil/Armodafinil: These wakefulness-promoting agents are widely used to manage excessive daytime sleepiness in narcolepsy. However, they are not indicated for cataplexy.

Pipeline and Emerging Therapies

The development pipeline for narcolepsy includes novel mechanisms of action aimed at improving tolerability, efficacy, and addressing different facets of the disease. While specific drugs in late-stage development directly challenging Xyrem's core indications are limited, the presence of Wakix and the ongoing research signify a growing competitive environment.

Generic Competition Impact

The introduction of generic sodium oxybate is expected to significantly impact Xyrem's market share and pricing.

• Price Erosion: Generic competition typically leads to substantial price reductions, affecting brand-name drug revenues.
• Market Share Shift: Prescribers may switch to lower-cost generic alternatives, leading to a decline in Xyrem's market share.
• Pharmacy Benefit Manager (PBM) Influence: PBMs may favor preferred generic placements on formularies, further accelerating the shift.

What are the Key Investment Considerations?

For R&D and investment decisions, evaluating Xyrem's lifecycle management, patent defense strategy, and the evolving competitive landscape is critical.

Factors Influencing Future Revenue

• Generic Erosion Timeline: The speed and extent of generic entry will directly influence revenue projections for Jazz Pharmaceuticals.
• Market Penetration of Wakix: The continued growth and market acceptance of Wakix will impact the overall narcolepsy market size and Xyrem's relative share.
• Jazz Pharmaceuticals' Lifecycle Management: Jazz's strategies for its existing narcolepsy franchise, including potential next-generation products or life-cycle extensions, will be important.
• Regulatory Environment: Changes in regulatory policies regarding narcolepsy treatments or controlled substances could influence market dynamics.

R&D Opportunities

• Novel Mechanisms for Narcolepsy: Research into new drug targets or delivery methods for narcolepsy symptoms, particularly those that address unmet needs not fully covered by current therapies.
• Improved Tolerability Profiles: Development of drugs with better side-effect profiles compared to existing treatments.
• Combination Therapies: Investigating the potential of combining existing or novel agents to achieve synergistic therapeutic effects.

Strategic Implications

Companies looking to enter or expand in the narcolepsy market must account for:

• The established presence of Xyrem and Wakix.
• The anticipated impact of generic sodium oxybate.
• The potential for new, innovative treatments to disrupt the market.
• The specialized nature of narcolepsy treatment, requiring engagement with key opinion leaders and patient advocacy groups.

Key Takeaways

Xyrem has been the cornerstone treatment for narcolepsy, supported by strong patent protection and regulatory exclusivities. However, its market exclusivity is diminishing due to ongoing patent litigation and the impending or current introduction of generic sodium oxybate. Wakix represents the most significant direct competitor, offering a distinct therapeutic profile. Investment and R&D strategies in the narcolepsy space must now consider the accelerating impact of generic competition on Xyrem's revenue and the ongoing innovation from competitors like Harmony Biosciences.

Frequently Asked Questions

What is the primary indication for Xyrem?

Xyrem is indicated for the treatment of cataplexy and excessive daytime sleepiness in patients diagnosed with narcolepsy.

Which company manufactures Xyrem?

Xyrem is manufactured by Jazz Pharmaceuticals.

What is the main competitor to Xyrem?

Wakix (pitolisant), manufactured by Harmony Biosciences, is the primary direct competitor to Xyrem.

Has Xyrem lost all patent protection?

While some foundational patents have expired or been successfully challenged, Jazz Pharmaceuticals has engaged in extensive litigation to defend its intellectual property. Generic entry is occurring through various pathways.

Are there any non-pharmacological treatments for narcolepsy?

Non-pharmacological management strategies for narcolepsy include scheduled naps, good sleep hygiene, and lifestyle adjustments, which often complement pharmacotherapy.

Citations

[1] Jazz Pharmaceuticals plc. (2023). 2022 Annual Report on Form 10-K. Retrieved from https://www.sec.gov/ix?doc=/Archives/edgar/data/1060595/000162828023001221/jazz-20221231.htm

[2] National Institute of Neurological Disorders and Stroke. (n.d.). Narcolepsy: Fact Sheet. Retrieved from https://www.ninds.nih.gov/health-information/fact-sheets/narcolepsy

[3] U.S. Food & Drug Administration. (n.d.). Applications with Orphan Drug Exclusivity. Retrieved from https://www.fda.gov/drugs/development-approval-process-drugs/applications-orphan-drug-exclusivity (Note: Specific Xyrem ODE status is reflected in historical approvals and may not be directly listed in a general FDA ODE table).

[4] Harmony Biosciences. (2019, August 15). FDA Approves Wakix® (pitolisant) as First and Only Treatment for Cataplexy and Excessive Daytime Sleepiness in Narcolepsy. [Press release]. Retrieved from https://www.harmonybiosciences.com/newsroom/fda-approves-wakix-pitolisant-as-first-and-only-treatment-for-cataplexy-and-excessive-daytime-sleepiness-in-narcolepsy/